rapid-acting therapies

R&D

pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.